Arecor Therapeutics plc announced a research collaboration with Medtronic plc to develop a novel, high concentration, thermostable insulin for use by Medtronic's Diabetes business in a next-generation implantable pump. This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy. This collaboration has the potential to allow for the continued care of these patients with an insulin that may minimise the need for pump maintenance interventions and expand the utility for physicians, whilst saving healthcare costs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
146.5 GBX | +11.83% | +7.33% | -19.73% |
12:08pm | Arecor Therapeutics' Investigational Insulin Shows Fast Absorption in Early-stage Study | MT |
11:00am | Arecor Therapeutics hails positive profile for insulin AT278 | AN |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
146.5 GBX | +11.83% | +7.33% | 50.98M | ||
84.51 USD | -1.64% | +1.19% | 114B | ||
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.73% | 50.98M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- AREC Stock
- News Arecor Therapeutics plc
- Arecor and Medtronic Diabetes Collaboration